What Is Aytu BioPharma, Inc. (AYTU) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aytu BioPharma, Inc. is potentially undervalued at its current price of $2.22. Based on our 13-model framework, Aytu BioPharma, Inc.'s intrinsic value is estimated at a composite fair value of $5.98 — representing +169.5% implied upside — with 9 out of 11 active models confirming this thesis. Model dispersion is worth noting: EROIC targets $12.31 (+454.3%), versus ML-RIV at $0.12 (-94.6%). This +548.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About AYTU?
11 of 13 models are currently active for AYTU. Of these, 10 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates AYTU's intrinsic value at $2.25, implying +1.3% upside from the current price. See which stocks rank higher →
How Does AYTU Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, AYTU ranks #126 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Aytu BioPharma, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is AYTU a Value Trap?
CirclFi's Value Trap algorithm assigns AYTU a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Aytu BioPharma, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Aytu BioPharma, Inc. is rated at 6.0/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +548.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AYTU valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AYTU's 11 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad